title: Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
abstract: Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology.
authors: Morton
authors: M
authors: Scheinberg
authors: Gilberto
authors: G
authors: Castañeda-Hernández
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000592:standards* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001688:Biological Products / Q000592:standards / Q000627:therapeutic use; D059451:Biosimilar Pharmaceuticals / Q000592:standards* / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence; D006801:Humans; D000069285:Infliximab; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001688:Biological Products; D059451:Biosimilar Pharmaceuticals; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab